Author

Violeta Serra

Vall d'Hebron Institute of OncologyORCID 0000-0001-6620-1065Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Organism:human· 3 Research Focus:differential expression· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Adrià Aterido· 1 shared Alba Llop‐GuevaraiD· 1 shared Alba Mas MalavilaiD· 1 shared Alexandra–Chloé VillaniiD· 1 shared Amanda J. CompadreiD· 1 shared Ana Maria CorralizaiD· 1 shared Ana P. VivancosiD· 1 shared Andrea R. HagemanniD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Adrià Aterido

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ImmunologyNature MedicinePeer-reviewedJan 12, 2026

Interpretable Inflammation Landscape of Circulating Immune cells

Laura Jiménez-Gracia, Davide Maspero, Sergio Aguilar-Fernández…·Holger Heyn

This paper constructs a single-cell atlas of circulating immune cells to understand inflammation across diseases and develops a classifier for inflammatory diseases.

26 citationstop 1%

humanscRNA-seq

𝕏 PostBluesky

Cancer BiologyJournal of Clinical InvestigationPeer-reviewedMay 20, 2025

Replication stress marker phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer

Angela M. Schab, Amanda J. Compadre, Rikki Drexler…·Mary Margaret Mullen

This study identifies phospho-RPA2 as a biomarker predicting response to platinum and PARP inhibitors in HR-proficient ovarian cancer, showing higher pathologic complete response and longer survival in pRPA2-High tumors.

11 citationstop 5%

humanimaging

𝕏 PostBluesky

Cancer BiologyCell Reports MedicinePeer-reviewedFeb 1, 2025

Evaluation of homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional tissue-based immunofluorescence assays

Sara Arce‐Gallego, Pablo Cresta Morgado, Luisa Delgado-Serrano…·Joaquín Mateo

This study evaluates homologous recombination repair status in metastatic prostate cancer using next-generation sequencing and RAD51 immunofluorescence assays, finding strong correlation between genomic and functional HRR loss.

11 citations

humanbulk RNA-seq

𝕏 PostBluesky